BioSenic S.A. announced a positive update to its ongoing Phase IIb clinical trial with its allogeneic bone cell therapy product, ALLOB. BioSenic has utilized scientific advances and market knowledge in feature healing and scientific advances in radiology to initiate positive modifications to its Phase IIb ALLOB trial. As a result, the study has advanced from seeking pure basic clinical assessments to involving more quantitative data.

This will allow for a superior significance analysis. This advance in the trial results assessment has been achieved through advances in radiographic procedures enabling increased clarity in statistical interpretation. As a result, BioSenic has decided, based on consultation with its external biostatistical advisors, that clinical investigators may now complete the recruitment of patients.

The cohort of treated patients, amounting to 57 patients, is found to be sufficient for a sufficient level of significance. Results from ALLOB Phase IIb trial shall now be made three months after difficult fracture and infusion of the ALLOB cells in the wounded sites of the 57 patients recruited. BioSenic expects to deliver decisive key results from this Phase IIb trial in second quarter of 2023.

The updated statistical analysis plan replaces the primary endpoint which now evaluates the difference between the placebo group and the experimental, ALLOB group in function of its compounded score from radiographic data collected after three months of treatment. BioSenic's new statistical analysis plan leads to a more objective scoring for judging the result of its innovative cell repair treatment. A RUST score difference higher than 1.26 will be considered statistically relevant.

A quantitative evaluation of the progress of the healing status of each patient will be given on a scale of a RUST score between 4 (no union) and 12 (complete healing), through a careful radiographic evaluation by two independent specialists. BioSenic considers this new statistical analysis corresponds more appropriately to the general conditions of the trial, its overall timing and expected evaluation power. The actual cohort of patients is considered to be wide enough to reach significance for its new critical ALLOB efficacy primary endpoint.

The ALLOB Phase IIb trial will also gather results on specific clinical evaluation criteria (secondary endpoints) and safety aspects, in accordance with the original study protocol. Treated patients will continue to be evaluated until full completion of the safety part of the study, as a follow-up of two years for each treated patient. Further to the decision to end recruitment and proceed towards a full set of meaningful results, the ALLOB subscription rights shall become exercisable based on the results at month three after patient treatment, if the difference in the mean RUST scores between the placebo's arm patient population and the treated ALLOB population is found higher than 1.26 in the new statistical analysis on the effectively recruited 57 patients.

The BioSenic Board adopts the view that the new exercise criteria does not reduce the global advantages granted to the ALLOB subscription rights holders.